Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome

被引:100
作者
Choquet-Kastylevsky, G
Intrator, L
Chenal, C
Bocquet, H
Revuz, J
Roujeau, JC
机构
[1] Univ Paris 12, Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France
[2] Univ Paris 12, Hop Henri Mondor, Dept Immunol, F-94010 Creteil, France
关键词
D O I
10.1046/j.1365-2133.1998.02559.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Hypersensitivity syndrome (HSS) usually refers to severe drug eruption associated with systemic symptoms and eosinophilia. Interleukin (a)-5 regulates eosinophil counts with the help of IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Blood IL-5 levels have been reported to be increased in patients with eosinophila secondary to parasitic infections or idiopathic eosinophilia. but have never been evaluated in drug-induced eosinophilia. The aim of our study was to determine whether IL-5, IL-3 and GM-CSF are involved in eosinophilia in patients with drug-induced HSS. Plasma levels of IL-3, IL-5 and GM-CSF were assayed by ELISA in seven patients with drug-induced HSS, in eight patients with cutaneous adverse drug reactions not associated with eosinophilia, and in five patients with eosinophilia unrelated to drug treatment. IL-5 levels were normal in all eight patients with drug eruptions without eosinophilia, and increased in five of the seven patients with HSS. In the latter patients, IL-5 levels peaked several days before highest eosinophil counts were noted, and returned to normal within a few days, even when eosinophilia persisted. In patients with eosinophilia unrelated to drug treatment, IL-5 levels, although significantly increased, remained lower than in HSS patients. IL-3 and GR I-CSF could not be detected in any group, at any time. Our results show that IL-5 is involved in drug-related eosinophilia. As IL-5 production was only Involved in the early stages of the reaction, it is suggested that IL-5 mainly derives from activated lymphocytes rather than eosinophils. Our results support the clinical relevance of previous in vitro findings. Further studies are needed to test whether assays of IL-5 production by lymphocytes of patients stimulated by the suspected drug and/or its metabolites, are useful in establishing causality in drug-induced reactions associated with eosinophilia.
引用
收藏
页码:1026 / 1032
页数:7
相关论文
共 39 条
  • [31] TSUTSUI H, 1992, J IMMUNOL, V149, P706
  • [32] PATCH TESTING WITH CARBAMAZEPINE - REINDUCTION OF AN EXFOLIATIVE DERMATITIS
    VAILLANT, L
    CAMENEN, I
    LORETTE, G
    [J]. ARCHIVES OF DERMATOLOGY, 1989, 125 (02) : 299 - 299
  • [33] Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung
    Venge, J
    Lampinen, M
    Hakansson, L
    Rak, S
    Venge, P
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (05) : 1110 - 1115
  • [34] ANTICONVULSANT HYPERSENSITIVITY SYNDROME
    VITTORIO, CC
    MUGLIA, JJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (21) : 2285 - 2290
  • [35] WELLER PF, 1991, NEW ENGL J MED, V324, P1110
  • [36] Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis
    Wolkenstein, P
    Chosidow, O
    Flechet, ML
    Robbiola, O
    Paul, M
    Dume, L
    Revuz, J
    Roujeau, JC
    [J]. CONTACT DERMATITIS, 1996, 35 (04) : 234 - 236
  • [37] METABOLIC PREDISPOSITION TO CUTANEOUS ADVERSE DRUG-REACTIONS - ROLE IN TOXIC EPIDERMAL NECROLYSIS CAUSED BY SULFONAMIDES AND ANTICONVULSANTS
    WOLKENSTEIN, P
    CHARUE, D
    LAURENT, P
    REVUZ, J
    ROUJEAU, JC
    BAGOT, M
    [J]. ARCHIVES OF DERMATOLOGY, 1995, 131 (05) : 544 - 551
  • [38] YAMAGUCHI Y, 1990, EXP HEMATOL, V18, P1152
  • [39] Zanni MP, 1997, J IMMUNOL, V158, P1139